Boehringer Ingelheim India Private Limited

Boehringer Ingelheim India Private Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
CIN U24230MH2003PTC143499 Incorporated 11 December 2003 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Private Limited Company pharma Fortune MNC 500 · #371
Data last updated
Revenue · FY 2026
₹665.16 Cr
▼ 37% YoY
Net profit · FY 2026
₹20.36 Cr
Net margin 3.1%
EBITDA · FY 2026
₹46.63 Cr
EBITDA margin 7%
Authorised capital
₹6.47 Cr
Registered with MCA
Paid-up capital
₹6.47 Cr
Issued & subscribed
Company age
23 yrs
Est. 2003
Employees · EPFO
744
Provident fund records
Directors on board
3
As per MCA filings

About Boehringer Ingelheim India Private Limited

Data last updated:

Boehringer Ingelheim India Private Limited is a private limited company based in Mumbai, Maharashtra, India, a subsidiary of Boehringer Ingelheim Auslandsbeteiligungs Gmbh. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 11 December 2003 and has been in existence for over 23 years.

Boehringer Ingelheim India is ranked #371 on the Fortune MNC 500 India (2026).

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24230MH2003PTC143499. Its GSTIN is 27AACCB2979C1ZR (Maharashtra). The company holds 18 GST registrations, of which 10 are active.

The company has an authorised share capital of ₹6.47 Cr and a paid-up capital of ₹6.47 Cr. It is led by directors including Sandipkumar Rameshchandra Agrawal and Sanjay Srivastava.

Its last annual general meeting (AGM) was held on 23 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Unit No. 202 2nd Floor Godrej 2 Pirojshah Nagar, Eastern Express Highway Vikhroli East Mumbai, Maharashtra, India – 400079.

As per the financials filed for FY 2026, the company reported a revenue of ₹665.16 Cr, a decline of 37% compared to the previous year. For the same year it recorded a net profit of ₹20.36 Cr (net margin 3.1%) and EBITDA of ₹46.63 Cr (EBITDA margin 7%). Revenue has declined at a compounded annual rate (CAGR) of 16% over three years and 11% over five years.

The company has about 744 employees on its provident fund (EPFO) records.

The company is associated with 1 brand: Boehringer Ingelheim. Court records list 66 cases involving the company, including 40 filed by the company and 26 filed against it; 26 cases are pending. The company has 3 deals on record (3 rights issues); the latest was in February 2017. The company has 4 MSME Form 1 returns on record between 2018 and 2021, listing 8 overdue payments to 3 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website boehringer-ingelheim.in.

Company details

CIN U24230MH2003PTC143499
Registration Number 143499
Incorporation Date 11 December 2003
ROC Mumbai
Listing Status Unlisted
Company Status Active
Date of Last AGM 23 September 2025
Date of Balance Sheet 31 March 2026
Parent Company Boehringer Ingelheim Auslandsbeteiligungs Gmbh
Compliance Status Active Compliant
Key People
Sandipkumar Rameshchandra Agrawal Director Sanjay Srivastava Director Shriya Mandar Oak Director

Recognitions & Rankings of Boehringer Ingelheim India

Fortune MNC 500 India 2026 edition
Rank#371
Total income
₹933 Cr
Profit
₹44 Cr
Last year #359

Contact details

Boehringer Ingelheim India Private Limited's registered office is in Mumbai, Maharashtra. Its website is boehringer-ingelheim.in. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    boehringer-ingelheim.in
  • Social Media
  • Registered Address
    Unit No. 202 2nd Floor Godrej 2 Pirojshah Nagar, Eastern Express Highway Vikhroli East Mumbai, Maharashtra, India – 400079
  • Industry
    Pharma, Drug Formulation & Development, Animal Pharmaceuticals & Healthcare

To see the full contact details of Boehringer Ingelheim India Private Limited, buy the company report.

Comprehensive company report
Boehringer Ingelheim India Private Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Boehringer Ingelheim India operates one associated brand: Boehringer Ingelheim. Each brand links to its own profile.

BrandDescriptionWebsite
Boehringer Ingelheim
Generic drugs and clinical research services are provided globally.boehringer-ingelheim.com

Business activity

The main business activity of Boehringer Ingelheim India is wholesale and retail trade; repair of motor vehicles and motorcycles. In detail, this covers wholesale trade, except of motor vehicles and motorcycles.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
GWholesale and retail trade; repair of motor vehicles and motorcycles46Wholesale trade, except of motor vehicles and motorcycles

To see the full business activity and turnover split of Boehringer Ingelheim India Private Limited, buy the company report.

Financials of Boehringer Ingelheim India Private Limited

FY 2026 filings available

Boehringer Ingelheim India Private Limited reported revenue of ₹665.16 Cr (down 37% YoY) for FY 2026.

Revenue · FY 2026
₹665.16 Cr ▼ 37%
Net profit · FY 2026
₹20.36 Cr margin 3.1%
EBITDA · FY 2026
₹46.63 Cr margin 7%

Compounded Annual Growth Rate (CAGR)

Revenue CAGR growth
1 year
▼ 37%
3 years · compounded
▼ 16%
5 years · compounded
▼ 11%
EBITDA CAGR growth
1 year
▼ 40%
3 years · compounded
▼ 6%
5 years · compounded
▼ 16%

Revenue has declined at a compounded annual rate (CAGR) of 11% over five years, including a 37% fall in the latest year. EBITDA fell 40% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.

Financial Statement Summary

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22
Profit and Loss Statement
Revenue from Operations
Other Income
Total Revenue₹665.16 Cr
Cost of Materials Consumed
Employee Benefit Expense
Finance Costs
Depreciation and Amortisation
Other Expenses
Total Expenses
EBITDA₹46.63 Cr
Profit Before Tax
Tax Expense
Net Profit (PAT)₹20.36 Cr
Balance Sheet
Share Capital
Reserves and Surplus
Net Worth (Total Equity)
Long-term Borrowings
Short-term Borrowings
Trade Payables
Total Liabilities
Fixed Assets
Investments
Inventories
Trade Receivables
Cash and Bank Balance
Total Assets

Financial Ratios

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22
Profitability
EBITDA Margin7%
Net Profit Margin3.1%
Return on Equity (ROE)
Return on Capital Employed (ROCE)
Return on Assets (ROA)
Liquidity and Debt
Current Ratio
Quick Ratio
Debt-to-Equity Ratio
Interest Coverage Ratio
Efficiency and Growth
Asset Turnover
Receivable Days
Payable Days
Inventory Days
Revenue Growth
Net Profit Growth

To see the full financial statements and ratios of Boehringer Ingelheim India Private Limited, buy the company report.

Board of directors of Boehringer Ingelheim India Private Limited

Boehringer Ingelheim India has 3 current directors and 16 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Sandipkumar Rameshchandra AgrawalDirector11 Oct 20179 Years 0 MonthsCurrent
Sanjay SrivastavaDirector21 Nov 20223 Years 11 MonthsCurrent
Shriya Mandar OakDirector23 May 20242 Years 5 MonthsCurrent
View all directors

Auditor

Boehringer Ingelheim India Private Limited is audited by B S R & Co. LLP for the financial year 2026.

Auditor firmFinancial yearFirm registration number
B S R & Co. LLPFY 2026101248W/W-100022

Shareholding

The shareholding of Boehringer Ingelheim India Private Limited is on record for 5 financial years, the latest being FY 2026, split between promoters, domestic institutions, foreign institutions, public shareholders and others.

Shareholder categoryFY 2026FY 2025FY 2024FY 2023FY 2022
Promoters
Domestic institutional investors (DII)
Foreign institutional investors (FII)
Public
Others

To see the full shareholding pattern of Boehringer Ingelheim India Private Limited, buy the company report.

Deals & funding

Boehringer Ingelheim India Private Limited has 3 deals on record (3 rights issues); the latest was in February 2017.

Total deals
3
Rights issues
3

Deals on record (3 of 3)

WhenDealAmountParties
Feb 2017Rights issue₹156 CrInvestors: Boehringer Ingelheim Auslanosbeteiligungs GMBH
Mar 2016Rights issue₹19 CrInvestors: Boehringer Ingelheim Auslanosbeteiligungs GMBH
Mar 2015Rights issue₹14.15 CrInvestors: Boehringer Ingelheim Auslanosbeteiligungs GMBH

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

Boehringer Ingelheim India Private Limited has 4 MSME Form 1 returns on record between 2018 and 2021, listing 8 overdue payments to 3 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (3 of 3)

SupplierAmount dueDue sinceReported on
Sne Business India Private Limited
an individual supplier
an individual supplier

To see the full MSME payment records of Boehringer Ingelheim India Private Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Employees & EPFO

Boehringer Ingelheim India Private Limited has a workforce of 744 employees on its EPFO records as of Apr 06, 2024, across 1 active EPFO establishment.

Employee count
744
Active EPFO establishments
1
Employee growth
-13.29%

GST

Boehringer Ingelheim India has 18 GST registrations: 10 active and 8 cancelled or inactive. The first 4 active GSTINs are listed below.

Total GSTINs
18
Active
10
Cancelled / inactive
8
GSTINStateStatusRegistered on
27AACCB2979C1ZRMaharashtraActive01 Jul 2017
27AACCB2979C2ZQMaharashtraActive04 Aug 2017
06AACCB2979C1ZVHaryanaActive01 Jul 2017
08AACCB2979C1ZRRajasthanActive01 Jul 2017

To see the full GST registrations and return filing status of Boehringer Ingelheim India Private Limited, buy the company report.

Recent activity

Boehringer Ingelheim India Private Limited has 18 board changes on record since 2008: 4 appointments and 14 cessations. The latest: Shriya Mandar Oak ceased to be Additional Director on 19 Sep 2024.

Filing
Boehringer Ingelheim India Private Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai.
AGM
Boehringer Ingelheim India Private Limited last Annual general meeting of members was held on 23 Sep 2025 as per latest MCA records.
Ceased
Shriya Mandar Oak ceased to be Additional Director.
Appointed
Shriya Mandar Oak was appointed as Director.
Ceased
Sanjay Srivastava ceased to be Additional Director.
Ceased
Gagandeep Singh Bedi ceased to be Additional Director.
Appointed
Gagandeep Singh Bedi was appointed as Managing Director.
Appointed
Sanjay Srivastava was appointed as Director.
Ceased
Delvin Jacob Mathews ceased to be Director.
Ceased
Vani Manja ceased to be Director.
Ceased
Sharad Tyagi ceased to be Managing Director.
Ceased
Sandipkumar Rameshchandra Agrawal ceased to be Additional Director.

9 earlier events are in the company report.

News

Frequently asked questions

Boehringer Ingelheim India is an active private limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 11 December 2003 (23+ years old) and is registered under CIN U24230MH2003PTC143499.

Boehringer Ingelheim India has 3 current directors:

The latest financial statements of Boehringer Ingelheim India on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 23 September 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Boehringer Ingelheim India is 27AACCB2979C1ZR, registered in Maharashtra. The company has 18 GST registrations in all, of which 10 are active and 8 are cancelled or inactive. Other active GSTINs include 27AACCB2979C2ZQ (Maharashtra), 06AACCB2979C1ZV (Haryana), 08AACCB2979C1ZR (Rajasthan).

The CIN (Corporate Identification Number) of Boehringer Ingelheim India is U24230MH2003PTC143499. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Boehringer Ingelheim India has 66 court cases on record: 40 filed by the company and 26 filed against it. 26 are pending. Most are in the high courts.

Boehringer Ingelheim India was incorporated on 11 December 2003, making it 23+ years old. It is registered with the Registrar of Companies, Mumbai.

Boehringer Ingelheim India has 3 deals on record (3 rights issues); the latest was in February 2017.

Shriya Mandar Oak ceased to be Additional Director on 19 Sep 2024. Shriya Mandar Oak was appointed as Director on 23 May 2024. Sanjay Srivastava ceased to be Additional Director on 24 Sep 2023. Boehringer Ingelheim India has 18 board changes on record in total.

Boehringer Ingelheim India has 4 MSME Form 1 returns on record between 2018 and 2021, listing 8 overdue payments to 3 micro and small suppliers. The latest return was filed on 28 Apr 2021.

Boehringer Ingelheim India can be reached through the website boehringer-ingelheim.in. Its registered office is in Mumbai, Maharashtra, India.